164 related articles for article (PubMed ID: 37861217)
1. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL; Dayan CM; Chatenoud L; Sumnik Z; Simmons KM; Szypowska A; Gitelman SE; Knecht LA; Niemoeller E; Tian W; Herold KC;
N Engl J Med; 2023 Dec; 389(23):2151-2161. PubMed ID: 37861217
[TBL] [Abstract][Full Text] [Related]
2. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
3. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
4. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
5. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
Hagopian W; Ferry RJ; Sherry N; Carlin D; Bonvini E; Johnson S; Stein KE; Koenig S; Daifotis AG; Herold KC; Ludvigsson J;
Diabetes; 2013 Nov; 62(11):3901-8. PubMed ID: 23801579
[TBL] [Abstract][Full Text] [Related]
6. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
7. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
[TBL] [Abstract][Full Text] [Related]
8. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
[TBL] [Abstract][Full Text] [Related]
9. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Mathieu C; Wiedeman A; Cerosaletti K; Long SA; Serti E; Cooney L; Vermeiren J; Caluwaerts S; Van Huynegem K; Steidler L; Blomme S; Rottiers P; Nepom GT; Herold KC;
Diabetologia; 2024 Jan; 67(1):27-41. PubMed ID: 37782353
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
Grando Alves G; Cunha L; Henkes Machado R; Lins de Menezes V
Diabetes Obes Metab; 2024 Jul; 26(7):2652-2661. PubMed ID: 38602411
[TBL] [Abstract][Full Text] [Related]
12. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
13. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
Forlenza GP; McVean J; Beck RW; Bauza C; Bailey R; Buckingham B; DiMeglio LA; Sherr JL; Clements M; Neyman A; Evans-Molina C; Sims EK; Messer LH; Ekhlaspour L; McDonough R; Van Name M; Rojas D; Beasley S; DuBose S; Kollman C; Moran A;
JAMA; 2023 Mar; 329(12):990-999. PubMed ID: 36826844
[TBL] [Abstract][Full Text] [Related]
14. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR; DiMeglio LA; Rendell MS; Felner EI; Dostou JM; Gitelman SE; Patel CM; Griffin KJ; Tsalikian E; Gottlieb PA; Greenbaum CJ; Sherry NA; Moore WV; Monzavi R; Willi SM; Raskin P; Moran A; Russell WE; Pinckney A; Keyes-Elstein L; Howell M; Aggarwal S; Lim N; Phippard D; Nepom GT; McNamara J; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):284-94. PubMed ID: 24622414
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Nourelden AZ; Elshanbary AA; El-Sherif L; Benmelouka AY; Rohim HI; Helmy SK; Sayed MK; Ismail A; Ali AS; Ragab KM; Zaazouee MS
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1895-1904. PubMed ID: 33302842
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
17. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
McVean J; Forlenza GP; Beck RW; Bauza C; Bailey R; Buckingham B; DiMeglio LA; Sherr JL; Clements M; Neyman A; Evans-Molina C; Sims EK; Messer LH; Ekhlaspour L; McDonough R; Van Name M; Rojas D; Beasley S; DuBose S; Kollman C; Moran A;
JAMA; 2023 Mar; 329(12):980-989. PubMed ID: 36826834
[TBL] [Abstract][Full Text] [Related]
19. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]